ALMS

Alumis (ALMS)

About Alumis (ALMS)

Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.

Details

Daily high

$24.72

Daily low

$22.50

Price at open

$22.55

52 Week High

$30.60

52 Week Low

$2.76

Market cap

3.1B

Dividend yield

0.00%

Volume

198,298

Avg. volume

1.0M

P/E ratio

-8.21

Alumis News